Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
Abstract Aim There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods This one‐week, prospective, single‐arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18-64 or 15 mg if age ≥ 65 years) for insomnia includ...
Saved in:
Main Authors: | Taro Kishi (Author), Kenji Sakuma (Author), Makoto Okuya (Author), Kohei Ninomiya (Author), Kazuto Oya (Author), Momoko Kubo (Author), Yuki Matsui (Author), Ikuo Nomura (Author), Yuji Okuyama (Author), Shinji Matsunaga (Author), Nakao Iwata (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review
by: Taro Kishi, et al.
Published: (2021) -
Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020) -
Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020) -
Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021) -
Profile of suvorexant in the management of insomnia
by: Sutton EL
Published: (2015)